Although BCL-2 mutations are known to drive resistance to venetoclax in CLL by inhibiting the binding of venetoclax to its target (178), very limited data are available regarding the potential mutations in MCL-1 that may hinder the activity of MCL-1i. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.